Media Center

Our location for news, announcements and insider perspectives.


Ironwood Capital Connecticut Portfolio Company IsoPlexis: Response noted in non-Hodgkin patients

By on , In the News

Reprinted from BioCT, June 22, 2018

IsoPlexis has announced the publication of clinical data demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis’ Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma.

“We were excited to collaborate on this groundbreaking research,” said IsoPlexis Chief Executive Officer Sean Mackay. “Using our single-cell predictive profiling platform, leading oncology and immunotherapy researchers and clinicians were able to collect this data, which demonstrates a potential to be able to apply the right therapies to the right patients and continue to personalize cancer immunotherapies, as these therapies continue to provide significant benefits to patients worldwide.”


Leave a Reply

Your email address will not be published. Required fields are marked *